Psoriasis

Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses considerations to address unmet needs and identify appropriate treatment of patients with pustular psoriasis.

Adalimumab and infliximab were the most common biologic therapies associated with the onset of palmoplantar pustulosis and palmoplantar pustular psoriasis.

A JAMA Dermatology study found that greater exposure to air pollutants, such as carbon monoxide and fine particulate matter, were significantly associated with later psoriasis flares.

Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.

More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.

Poor agreement was identified regarding MRI- and classification-defined axial spondyloarthritis (axSpA) and inflammatory back pain diagnoses in patients with psoriatic disease.

Psoriasis developed in 1 in 4 patients with axial spondyloarthritis (axSpA) across a 6-year span, in which those with both conditions reported greater joint involvement and biologic use than those with only axSpA.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses treatment considerations for patients with different types of pustular psoriasis.

Psoriasis Area and Severity Index scores indicated that patients with moderate-to-severe psoriasis had improved skin clearance when treated with risankizumab compared with secukinumab treatment.

Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, speaks on cytokines involved in the pathophysiology in pustular psoriasis and off-label therapy use.

Patients with psoriatic disease and dermatologists reported their preferred strategies to improve cardiovascular disease risk management, with a specialist-led model of care touted by both groups.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.

Drs Lebwohl and Groves list support services to help with patient adherence.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Patients with comorbid psoriasis and psoriatic arthritis exhibited significantly higher rates of depression and anxiety vs those with psoriasis alone, whereas lifetime suicidality prevalence was not different between the 2 groups but still heightened compared with the general population.

Patients with psoriasis exhibited superior efficacy outcomes when treated with ultraviolet (UV)-based phototherapy plus other adjuvant therapies vs UV monotherapy, with similar safety profiles shown for both approaches.

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.

Patients with psoriasis who had comorbidities were associated with worse health-related quality of life and impaired treatment outcomes with conventional therapy, whereas biologic treatments maintained high efficacy despite presence of co-occuring conditions.

Treatment with the interleukin-36 inhibitor spesolimab was associated with improved lesion clearance vs placebo after one week, but also a greater incidence of infection and systemic drug reactions.

Dr Lebwohl explains how he can recognize who will respond early to psoriasis treatments and who won’t respond at all.

Bhavesh Shah, PharmD, elaborates on switching biologics in psoriasis treatment.

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.

Psoriasis severity and treatment outcomes were found to differ across US geographic regions, in which the East South Central and West South Central regions were associated with the greatest frequencies of very severe disease burden and decreased likelihood of achieving targeted response within 6 months of initiating biologic therapy.